Related Experiment Video

Updated: Aug 22, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Chronic angina pectoris: inadequacies of current therapy

John O Parker1

  • 1Division of Cardiology, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7. joparker@kingston.net

The American Journal of Geriatric Cardiology
|September 15, 2004
PubMed

Insights

Chronic angina affects millions, causing poor quality of life due to inadequate symptom control from current medications. New metabolic modulators offer effective angina treatment with a favorable side-effect profile.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic angina impacts over 6 million in the US, with increasing prevalence due to an aging population.
  • Current antianginal treatments often fail to provide adequate symptom control and are associated with side effects, leading to a poor quality of life.
  • No new drug classes for angina have emerged in over 20 years, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel agents that modulate myocardial metabolism for chronic angina treatment.
  • To assess the potential of these new agents to improve symptom control and quality of life in angina patients.

Main Methods:

  • Investigated new antianginal agents targeting myocardial metabolism.
  • Assessed antianginal efficacy, side-effect profile, and hemodynamic effects.

Main Results:

  • New agents modulating myocardial metabolism demonstrated antianginal efficacy.
  • These novel agents exhibited a favorable side-effect profile.
  • The new agents showed an absence of hemodynamic effects.

Conclusions:

  • Novel agents that modulate myocardial metabolism represent a promising new class of drugs for chronic angina.
  • These agents offer potential for improved symptom control and quality of life without adverse hemodynamic effects.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina I: Introduction01:30

Angina I: Introduction

Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...